哮喘联盟

   摘要
   重症哮喘定义为需要很大的药物负荷才能部分或完全控制临床症状。这对于全球哮喘患者和公共卫生事业而言都是巨大的负担。而改变这一现状，改善靶点药物和患者转归的关键在于就重症哮喘的病理生理机制有更深入的理解。

 

（上海交通大学医学院附属瑞金医院呼吸与危重症医学科 周剑平 万欢英 摘译）

（Respirology. 2018 Jan 9. doi: 10.1111/resp.13251. [Epub ahead of print]）

Pathophysiology of severe asthma: We've only just started.

Respirology. 2018 Jan 9. doi: 10.1111/resp.13251. [Epub ahead of print]

King GG et al.
 
Abstract
Severe asthma is defined by the high treatment requirements to partly or fully control the clinical manifestations of disease. It remains a problem worldwide with a large burden for individuals and health services. The key to improving targeted treatments, reducing disease burden and improving patient outcomes is a better understanding of the pathophysiology and mechanisms of severe disease. The heterogeneity, complexity and difficulties in undertaking clinical studies in severe asthma remain challenges to achieving better understanding and better outcomes. In this review, we focus on the structural, mechanical and inflammatory abnormalities that are relevant in severe asthma.